title: Prevention of Plasmodium falciparum malaria by Fansimef and Lariam in the northeastern part of Thailand.
abstract: Two studies were conduct in Thailand in order to find appropriate falciparum malaria prophylactic drug regimens. The first study was done during June - September 1987 with 363 soldiers who received Fansimef (MSP) 1 tab/week (group 1), 337 soldiers who received MSP 1 tab/2 week (group 2) and 165 soldiers who received chloroquine 300 mg base weekly plus Fansidar 1 tab/week (group 3). At the end of the study there were 9 and 13 falciparum malaria episodes in groups 1 and 2, respectively, with incidence rates of 0.8 and 1.8 cases/100 person-months (P-M). In group 3, the corresponding values were 30 episodes and an incidence of 7.2/100 P-M. For the second study which lasted from October 1987 - January 1988 in the same area, 498 soldiers were given Fansimef 1/2 tab/week (group 4), 499 soldiers were given Lariam 1/2 tab/week (group 5) and 247 soldiers were given chloroquine plus Fansidar (group 6). Thirty malaria episodes were found in group 4, for an incidence of 2.0/100 P-M. In group 5, 23 episodes were found, for an incidence of 1.6/100 P-M. In group 6, 74 episodes occurred, ie an incidence of 12.2/100 P-M. The incidence rates of malaria among Fansimef 1 tab weekly, Fansimef half dose weekly or Lariam half dose weekly were not significantly different but were different from chloroquine plus Fansidar groups. Adverse events in each group were mild.
authors.affiliation: Armed Forces Research Institute of Medical Sciences, Royal Thai Army Medical Department, Bangkok.
authors.forename: C
authors.initials: C
authors.lastname: Eamsila
authors.forename: P
authors.initials: P
authors.lastname: Singharaj
authors.forename: P
authors.initials: P
authors.lastname: Yooyen
authors.forename: P
authors.initials: P
authors.lastname: Chatnugrob
authors.forename: A
authors.initials: A
authors.lastname: Nopavong Na Ayuthya
authors.forename: H K
authors.initials: HK
authors.lastname: Webster
authors.forename: R
authors.initials: R
authors.lastname: Lasserre
authors.forename: M L
authors.initials: ML
authors.lastname: Mittelholzer
authors.forename: D
authors.initials: D
authors.lastname: Stürchler
mesh_terms: D000328:Adult; D000818:Animals; D000913:Antibodies, Protozoan / Q000302:isolation & purification; D001769:Blood / Q000469:parasitology; D002738:Chloroquine / Q000627:therapeutic use; D004338:Drug Combinations; D006801:Humans; D016778:Malaria, Falciparum / Q000517:prevention & control*; D008297:Male; D015767:Mefloquine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D008889:Military Personnel; D010963:Plasmodium falciparum / Q000276:immunology / Q000302:isolation & purification; D011739:Pyrimethamine / Q000627:therapeutic use*; D013413:Sulfadoxine / Q000627:therapeutic use*; D013785:Thailand; D000096926:Benzenesulfonamides
chemical_list: D000913:Antibodies, Protozoan; D002738:Chloroquine; D004338:Drug Combinations; D015767:Mefloquine; D011739:Pyrimethamine; D013413:Sulfadoxine; C001205:fanasil, pyrimethamine drug combination; C046846:mefloquine-sulfadoxine-pyrimethamine; D000096926:Benzenesulfonamides